Different risk factors for poor outcome between patients with positive and negative susceptibility vessel sign

J Neurointerv Surg. 2016 Oct;8(10):1001-5. doi: 10.1136/neurintsurg-2015-011999. Epub 2015 Sep 25.

Abstract

Purpose: The absence of the susceptibility vessel sign (negative SVS) on gradient-recalled echo or susceptibility-weighted imaging (SWI) in thrombolytic therapy has not been well studied. Since positive and negative SVS may have different components, we aimed to investigate the difference in risk factors for clinical outcome between patients with positive and negative SVS.

Methods: We retrospectively examined clinical and imaging data from 85 consecutive patients with acute ischemic stroke with middle cerebral artery occlusion who underwent SWI before intravenous thrombolysis (IVT). We then examined the predictors of negative SVS and the risk factors for a poor outcome (defined as modified Rankin Scale score ≥3) 3 months after IVT in subgroup analysis.

Results: Multivariate regression analysis indicated that previous antiplatelet use (OR 0.076; 95% CI 0.007 to 0.847; p=0.036) and shorter time from onset to treatment (OR 1.051; 95% CI 1.003 to 1.102; p=0.037) were inversely associated with poor outcome in patients with negative SVS, while higher baseline National Institutes of Health Stroke Scale (NIHSS) score was associated with poor outcome in patients with positive SVS (OR 1.222; 95% CI 1.084 to 1.377; p=0.001).

Conclusions: The risk factors for clinical outcome after IVT in patients with negative SVS may differ from those with positive SVS.

Keywords: MRI; Thrombolysis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Vessels / diagnostic imaging*
  • Brain Ischemia / diagnostic imaging*
  • Brain Ischemia / therapy*
  • Databases, Factual
  • Female
  • Humans
  • Image Processing, Computer-Assisted
  • Infarction, Middle Cerebral Artery / diagnostic imaging
  • Infarction, Middle Cerebral Artery / therapy
  • Magnetic Resonance Angiography
  • Male
  • Middle Aged
  • Observer Variation
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Factors
  • Stroke / diagnostic imaging*
  • Stroke / therapy*
  • Thrombolytic Therapy
  • Time-to-Treatment
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors